









4-8 December, 2017 I New Delhi











# Overview of Medical Device Clinical Investigation Regulations in Korea

5st Dec. 2017

Mi-jung Son

Deputy Director of Medical Devices Policy Division
Korea Ministry of Food and Drug Safety











## Mi-jung Son



# Deputy Director Medical Device Policy Division Korea MFDS

 In charge of legislating and streamlining laws & regulations on clinical & non-clinical trials for medical devices









## **Table of Contents**

- 1 Introduction to Clinical Trials in Korea
- Protocol Approvals and Required Materials
- Good Clinical Practice
- 4 Inspections and Designating Clinical Trial Institutions
- 6 Clinical Evaluation









## 1. Introduction to Clinical Trials in Korea












## Structure of MFDS Medical Device Regulations











## **Definition and Classification of Clinical Trials for Medical Devices**

A test or a study using human subjects in order to prove safety and effectiveness of the medical device used in a clinical trial/study

## Investigator Initiated Trials (IIT)

Clinical researchers <u>are performing a</u>
 <u>clinical trial/study autonomously</u>
 <u>without sponsors</u>

## Sponsor Initiated Trials (SIT – individual or organization)

#### **Feasibility Study**

 Clinical trial/study with a few subjects during a short period is done in its early development stage of medical device for investigating safety and effectiveness

### **Confirmatory Study**

 Clinical trial/study is designed and performed with <u>statistically</u> <u>significant numbers of subjects</u> for confirming safety and effectiveness










## Clinical Trial Approvals by year

### Increased number of clinical trial approvals for medical device approved by MFDS













## **Analysis for Clinical Trial Approvals for Medical Devices**

- Clinical trials for domestically developed products on the rise
  - A 60% year-on-year increase in manufacturing
  - Feasibility studies (22cases, Δ83.3%), Confirmatory studies (68cases, Δ838.8%), investigator-initiated studies (38cases, Δ100%)
  - apparatus machine (50 cases), medical products (30 cases), reagents for in-vitro diagnostic use (48 cases)
- An uplift in clinical trials for IVD products to be regarded as medical devices
  - A 43.6% year-on-year increase (manufacture increased by 60%, import decreased by 11%)
- Anticipated an increase of clinical trials for the applicable devices with the 4th industrial revolution
  - Anticipated a rapid increase of clinical trials for the applicable medical devices to rapidly increase for the emergence of AI, Rehabilitation Robots, 3D printed devices
  - 3 approval cases for protocol based on artificial intelligence ('17.9)










## Institutions Designated as Clinical Trial Centers for Medical Devices

## Clinical trial approvals in accordance IRBs

1 IRBs	2 Shared IRBs	Using Shared IRBs
134	14	8

- 1 IRBs reviewing clinical trials for medical devices only within the applying institution
- Shared IRBs reviewing clinical trials for medical devices within its own facility and clinical trials in other institutions
- (3) IRBs which cannot review clinical trials of medical devices in the applicable institution, resulting in reviewing in shared IRBs mentioned above.











## **Clinical Trials Management Systems**

Pre-Approval Management Post-Approval Management

- Approval of Clinical trials
- Accreditation of Clinical Trial Institutions

- Management of
  - Safety informations and ADE reports
  - Annual reports
  - Termination reports
  - Study reports
- Inspections









## **Medical Device Clinical Investigation Process**

Sites Accreditations

**MFDS** 

Sponsor (Manufacturer & Investigator)

## GMP Requirements GLP or Testing Institution recognized by MFDS

Conduct Preclinical Studies

(In vitro & In vivo testings)

- Develop Clinical Strategy
- Study Design Investigator
   /site CRO

30 working days

#### MFDS Review

-Protocol(Informed consent statistical Anal.plan -Data monitoring Plan

#### **Prepare**

Obtain Approval from MFDS & IRB

- Data Mgmt plan
- Statistical Anal.Plan

### Inspection

## MFDS GCP Requirements - Investigation site

- IRB
- Sponsor
- Investigator

#### Initiate & Manage

Enroll Patients Monitoring QC Audit Record & documents

#### Study Completion

Report
-Adverse Events

Review (80days)

Submission
Product Approval
Application with
Final clinical
Report

#### **IRB** Review

- Monitoring plan

**Develop Investigation** 

Plan & Submission

- Preclinical Study data

Agreement with

site/CRO/vendors

Protocol

- Clinical GMP certification









## 2. Protocol Approvals and Required Documents









## **Approval Procedure for Clinical Trial Protocol**

### **Application**

- Clinical Trial Plan (Protocol)
- Technical Document
- QMS for Clinical Trials



### **Review & Approval**

Review Period (30 working days)



#### **Clinical Trial**

Approval of clinical trial plans

- ➤ Who Must Apply : A person who is planning to perform clinical trials for medical devices is required to get an approval from the Minister of KOREA MFDS beforehand.
- ➤ When to Apply : Prior to initiate studies MFDS Approvals and IRB Approvals









## **Approvals for Clinical Trial Protocol**

## Clinical trials to be approved

- Clinical trials investigating or studying human subjects to prove safety and efficacy of medical devices that are not approved
- Clinical trials investigating and studying human subjects to prove safety and effectiveness of the intended use of devices other than approvals for medical devices on the market (indications, applied region)

## Clinical Trials exempted from MFDS approvals

- Clinical Trials to investigate adverse device events and observation of clinical efficacy for approvals of medical devices on the market
- Clinical trials to collect data on safety and efficacy related to approved performance and intended use of medical devices on the market
- Clinical trials for IVD medical devices designated by the ministry of MFDS









## Required Materials to Apply for Clinical Trials

#### **Protocols**

- Site Selection
- Investigator, sponsor and monitor responsibilities
- Investigational device description and method of use
- Study objects
- Study design and method
- Inclusion/Exclusion Criteria
- Number of Samples, statistical design, analysis plan
- Inspection and observation item
- Evaluation Criteria
- Primary and secondary endpoints
- Expected Adverse Event
- Safety Plan
- Informed Consent from
- Policy for the safety and protection of human subjects

#### **Technical Documents**

- Technical Document
  - Intended Use
  - Physical and Chemical properties
  - Electric and Mechanical Safety
  - Biological Safety
  - Radiation Safety
  - Electromagnetic Interference
  - Performance
  - Stability and sterilization
- Safety and Effectiveness Document
  - Origin or Course of development
  - Usage status overseas
  - Comparison with similar medical devices

#### **GMP**

GMP Certificate










## **Established a System Publishing Clinical Trials Approved**











## 3. Good Clinical Practice











## **Good Clinical Practice (General Requirements)**

- Comply with approved plan in a safe and scientific manner
- Only at the sites recognized by MFDS
- Select qualified investigator with expertise and ethical qualities
- Informed consents and human subject protection
- Not to be used other than clinical study purpose
- MFDS/IRB Approval
- Initiated within 2 years after approval
- Sponsors should provide investigator with the information to conduct properly
- Annual Reports
- Medical Devices manufactured under GMP
- Adverse Events Report and required records and reports
- Responsibilities of IRB, manufacturer, sponsor, investigator, monitor responsibilities
- Investigational Medical devices and labeling
- Monitoring of study









## **Good Clinical Practice**

#### **Clinical Trial Institutions & IRBs**

#### Clinical Trial Institutions

- Facilities
- Human Resources
- System
- SOP
- IRBs

#### **IRBs**

#### **Protocol Approvals shall** remain its independence

- Pre-notified meeting
- SOP renewals
- intensive Review

## **Investigators**

#### Implementing clinical trials

- Qualified by training and experience
- Understand & Follow Protocol
- Assign each role in trials
- Keep subject's agreement procedures
- Strengthening collaboration with IRB
- Protect Human Subject
- Intact relationship with Sponsor
   Device Control

Informed Consent

Records & Report



#### Plan, Monitor, Audit, Report

- Monitoring & Auditing
  - Same CRF and Source data
  - Correcting protocol violations
  - Training for CRA
- Report on safety issues and take necessary actions
- Quality Management of Study
- Selecting investigator
- Device control & Protect Human subject

#### **MFDS**

#### **Accredited Institutes Approval & Inspection**

- Inspections and Corrections, and improving regulations
  - Strengthening pre-, post-inspections
  - Updating related regulations
- Standardization & updating
- IRB-related regulations











## Informed Consents and its Exemption (leftover specimens)

- Clinical trials can be performed without written informed consents in case of clinical trials using leftover specimens when it fulfills the following requirements
  - Where it is practically impossible to obtain informed consent from a subject;
  - Where there is no particular reason for subjects to reject consent; and
  - Where the risk to subjects by taking part in the investigation is extremely low

### **Leftover Specimens**

- → A human sample left from a use in a medical institution for diagnostic or treatment purposes
- → A human sample left from extraction and use for a specific research purpose and for which a comprehensive consent was obtained from its donor on its use for other secondary purposes

Private information of the subject who offered the specimen should be kept in confidential in case of clinical trials using residual specimens without written informed consents









## **Definition of Adverse Event Reporting**

#### Adverse Event, AE

It refers to every unintended symptom and disease of subjects during clinical trials (it does not necessarily require to have cause and effect relations with medical devices for clinical trials)

#### Adverse Device Effect, ADE

It refers to every harmful and unintended reaction derived from medical devices for clinical trials (it cannot deny the interrelation with medical devices for clinical trials)

#### Serious AE-ADE

Adverse Events or Adverse Device Effects caused by medical devices used for clinical trials that fall under any of the followings

- 1) In case risks to human lives or death
- 2) In case there needs to extend duration of hospitalization or need to be hospitalized
- 3) In case of permanent or serious impairment, and malfunction
- 4) In case of malformation or abnormality of fetuses

#### Unexpected Adverse Device Effect, UADE

Aspects or risk level differs depending on adverse device effect based on relative information on available medical devices such as investigator's brochure or attached documents of medical devices

#### Unexpected serious ADE(Adverse Device Effects)

Subject to reporting to the MFDS









## **Adverse Event Reporting Process**











#### Sponsor







**Adverse Events** 



- ♦ Who to report : Serious Adverse Events (SAE)
- When to report: within period specified in the protocol
- What to report : medical device adverse events



- Who to report : Serious and unexpected Adverse Device Effects
- When to report
  - life-threatening cases or death: within 7 days otherwise: within 15 days
- What to report : medical device adverse events









# 4. Inspections and Designating Clinical Trial Institutions











## **Types of Inspections**



Periodic post-market inspection for clinical trial centers (evaluated depending on levels)



Whether to comply with KGCP for the product item applied for approval, etc.



An on-site inspection triggered by social issues, statistical analysis, medical device adverse events and civil petitions, etc.









## **Strategy of Inspections**

- Inspection of on-going and completed clinical trials
- Selection of trials based on risk assessment process and SIT
  - Development phases in the drug or device
  - Product types (Implant, Stent, Bone graft, Electrocardiographs, other)
  - Complexity of the trial design
  - Number of subjects enrolled
  - Therapeutic indications or areas
  - Study population (pediatric, other vulnerable, general)
  - Number of serious unexpected adverse medical device reaction at the clinical trial sites)









## **Administrative Disposition after Inspections**

#### **Violation**

Cases that have adversely affected safety, rights and well being of the subjects, and quality and integrity of the clinical trial results

#### Correction

Cases that might adversely affect safety, rights and well being of the subjects, and quality and integrity of the clinical trial results

#### Caution

Cases that are not likely to adversely affect safety, rights and well being of the subjects, and quality and integrity of the clinical trial results

#### Recommendations

Suggestions on how to improve quality of clinical trials for the future and to reduce the potential of deviation

#### **Administrative Disposition / Accusation**

#### Administrative Disposition

: warning, changing PI, suspension on the role of "designated IRB", 3 to 6 months suspension on implementing the applicable clinical trials, and cancelling the designation, etc.

#### Accusation

: sentenced to at most 3 years or fined no more than 30million won









## **Procedure to Designate Institutions for Clinical Trials**

- Definition of Clinical Trial Centers for Medical Devices
  - Institutions equipped with required facilities and taskforce for implementing clinical trials among medical institutions
  - Clinical trials for medical devices must be implemented in clinical trial institutions designated by the ministry of MFDS

### Application

- License for opening medical institutions
- SOP of clinical trial institutions and IRBs
- materials, etc. on how the IRB is composed

#### Document Review and Inspections

Processing period -15 working days

- institutions designated as clinical trial institutions for drugs
  - 12 working days

#### Designation

Issuing a letter of designation









## Required Documents to be Designated as Clinical Trial Institutions

- Required for submissions to be designated as a institution for medical device clinical trials
  - License to launch medical institutions
  - Regulation on administrative procedures, etc. required for clinical trials (taskforce, facilities and equipment, etc.)
  - Regulation on contract inspections
     (only applicable to institutions who intend to operate "Shared IRBs")
  - Regulations on operation of IRBs and materials of its composition
    - Require to attach contract of consignment to use "Shared IRBs"
  - Materials to prove that it falls under any of the followings
    - General hospitals
    - Teaching hospitals, teaching dental hospitals and teaching oriental medicine hospitals
    - Specialty hospitals
    - Hospitals for teaching singular professional subjects
    - Clinical trial centers in Osong High-tech Composite Medical Complex









## 5. Clinical Evaluation











## Approval for Medical Devices and Clinical Trials in Europe

Clinical Evaluation includes contemplating clinical literature, other post-market surveillance and risk management other than simple literature review implemented in pre-market management












## Approval for Medical Devices and Clinical Trials in Europe

Medical Device Directive of the EU was completely revised based on the groundbreaking changes in 2017, and it was transformed from the existing Directive to Regulation



- → A guide applying clinical evaluation
  - Medical Devices Directives Clinical Investigations, Clinical Evaluation: A Guide for Manufacturer and Notified Bodies Under Directives 93/42/EEC and 90/385/EEC(MEDDEV 2.7.1)
  - **MEDDEV 2.7.1** went through revision in June 2016, applying the 4th revision currently









## Requirements in Europe (Regulatory Authority: Notified Body)



- Clinical evaluation reports for every class of medical devices
- Class 1, 2
  - Clinical trial materials and clinical evaluation reports prepared based on the clinical trial materials, or
  - Clinical evaluation reports prepared based on literature materials of equivalent products, or
  - Clinical evaluation reports can be submitted, prepared based on pre-clinical data if there is no equivalent products in case of low risk devices (~2a)
- o Class 2. 3
  - Clinical evaluation reports including clinical trial materials that have used the applicable medical devices
  - Clinical evaluation reports prepared based on literature materials if there is an approved equivalent product in case of class 2 devices



#### PMS(Post-Market Surveillance)

- A scheme to make corrective actions by collecting and analyzing post-market information for every class of medical devices
- PMCF(Post-Market Clinical Follow-up studies)
  - A scheme to identify clinical safety and efficacy that are not identified when approved
- EU Surveillance System
  - A Scheme reporting safety information derived from inside and outside of Europe for all medical devices
  - Clinical evaluation data, PMS and PMCF documents should be updated and go through inspections in case of post-market inspections or renewal inspections for every class of devices
- Actively using DB for adverse event reporting such as MGRA and BfAm, and EUDAMED to be publicly available









## **US standards (Regulatory Authority : FDA)**



- Clinical Data submission requirements varies depending on risk levels of devices and whether it is a substantially equivalent product
  - Class 1 & 2 (510(k)): exempted from submitting clinical data if it is substantially equivalent, and requires clinical data if it is not substantially equivalent
  - Most Class 3 and some Class 2 Devices (PMA): risk-benefit analysis on clinical safety and efficacy
  - De Novo : clinical data and risk-benefit analysis on safety and efficacy



- PMS (Post-Market Surveillance)
  - A scheme investigating information on adverse events using implantable and high-risk devices and effects on patients
- PAS (Post-Approval Studies)
  - A scheme consistently evaluating safety and efficacy based on results of long-term monitoring on some PMA medical products subject to PMA
- RWE(Real World Evidence): Identify clinical safety and efficacy using Real World Data
  - Can help expanding clinical indications, be used as PMS and PAS materials, replaced as control group materials for clinical studies, used as supplementary data for post-market safety information, etc. and used as objective performance standards and information on intended use (released a guideline in Aug 31st in 2017)
- Encouraging DB of MAUDE and MEDSUN and then will be available on NEST









### **Considerations in Clinical Evaluation**

- ⇒ Should consider Clinical Evaluation of Europe and clinical inspection system of the US (considering real world data) in terms of managing the whole life-cycle of medical devices
- ⇒ Should analyze the meaning of clinical evaluation in terms of post-market management including post-market surveillance, adverse event reporting as well as pre-market management of medical devices
- Should contemplate specific inspection method for clinical evaluation reports as well as streamlining laws and regulations
- Should come up with improvement plans for effective safety management system of medical devices leading to preemptively respond to global regulatory changes
- Need capacity building of medical device inspectors









## Thank you for your attention

